Payment overview · 2025
General Payments
$445.77
25 reported records · 7 companies
Healthcare provider profile · identity verified
Hossein K Tabari, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · BOGALUSA, LA · NPI 1619032141
Verified facts
What the public records show
CMS Open Payments records show Hossein K Tabari, M.D. received $445.77 in general payments during 2025 across 25 reported records.
GlaxoSmithKline, LLC. accounted for 33.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Mounjaro, Trelegy Ellipta, Xifaxan.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trulicity by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APTIOM as an associated drug or biological on 11 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Aptiom by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $148.73 | 33.4% | 10 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $73.15 | 16.4% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $57.04 | 12.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $55.14 | 12.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.11 | 12.4% | 3 | 2025 |
| AKEBIA THERAPEUTICS INC | Unresolved — no canonical attribution shown | $36.19 | 8.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.41 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $445.77 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $148.73 | 10 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $73.15 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $55.11 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $40.73 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $37.85 | 2 | 2025 |
Source payment records
|
|||||
| Vafseo Normalized: vafseo |
Drug | AKEBIA THERAPEUTICS INC | $36.19 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 55 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
131 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
55 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | APTIOM open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 11 recipient NPIs · example record 1176658319 |
Aptiom · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 771 | 101 |
| Gabapentin | Gabapentin | 591 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 588 | 151 |
| Atorvastatin Calcium | Atorvastatin Calcium | 565 | 132 |
| Pantoprazole Sodium | Pantoprazole Sodium | 432 | 110 |
| Metoprolol Succinate | Metoprolol Succinate | 295 | 81 |
| Potassium Chloride | Potassium Chloride | 293 | 66 |
| Tramadol Hcl | Tramadol Hcl | 280 | 54 |
| Furosemide | Furosemide | 270 | 79 |
| Levothyroxine Sodium | Levothyroxine Sodium | 266 | 60 |
| Eliquis | Apixaban | 243 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 217 | 47 |
| Trazodone Hcl | Trazodone Hcl | 205 | 41 |
| Meloxicam | Meloxicam | 190 | 47 |
| Lisinopril | Lisinopril | 178 | 43 |
| Metformin Hcl | Metformin Hcl | 169 | 42 |
| Alprazolam | Alprazolam | 168 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 162 | 48 |
| Tizanidine Hcl | Tizanidine Hcl | 157 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 155 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 40 |
| Carvedilol | Carvedilol | 145 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 144 | 34 |
| Sucralfate | Sucralfate | 140 | 35 |
| Losartan Potassium | Losartan Potassium | 137 | 45 |
| Farxiga | Dapagliflozin Propanediol | 131 | 26 |
| Allopurinol | Allopurinol | 128 | 28 |
| Ondansetron Hcl | Ondansetron Hcl | 128 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 123 | 34 |
| Azithromycin | Azithromycin | 122 | 89 |
| Ibuprofen | Ibuprofen | 122 | 36 |
| Januvia | Sitagliptin Phosphate | 121 | 12 |
| Linzess | Linaclotide | 110 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 108 | 26 |
| Promethazine Hcl | Promethazine Hcl | 108 | 31 |
| Omeprazole | Omeprazole | 106 | 29 |
| Mirtazapine | Mirtazapine | 99 | 18 |
| Amoxicillin | Amoxicillin | 98 | 52 |
| Buspirone Hcl | Buspirone Hcl | 97 | 20 |
| Pregabalin | Pregabalin | 96 | 14 |
| Methylprednisolone | Methylprednisolone | 91 | 75 |
| Montelukast Sodium | Montelukast Sodium | 90 | 23 |
| Sevelamer Carbonate | Sevelamer Carbonate | 90 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 86 | 18 |
| Famotidine | Famotidine | 85 | 23 |
| Sertraline Hcl | Sertraline Hcl | 81 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 79 | 18 |
| Donepezil Hcl | Donepezil Hcl | 76 | 13 |
| Glimepiride | Glimepiride | 76 | 20 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 73 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 73 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 72 | 23 |
| Nifedipine Er | Nifedipine | 72 | 20 |
| Temazepam | Temazepam | 71 | 11 |
| Clonazepam | Clonazepam | 70 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 15 |
| Spironolactone | Spironolactone | 70 | 18 |
| Trulicity | Dulaglutide | 70 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 66 | 22 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 63 | suppressed |
| Diazepam | Diazepam | 63 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 63 | 20 |
| Memantine Hcl | Memantine Hcl | 62 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 19 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 55 | 14 |
| Colchicine | Colchicine | 55 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | 15 |
| Calcitriol | Calcitriol | 53 | 11 |
| Prosol | Parenteral Amino Acid 20% No.1 | 53 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 36 |
| Levetiracetam | Levetiracetam | 51 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 50 | suppressed |
| Ozempic | Semaglutide | 50 | 11 |
| Simvastatin | Simvastatin | 50 | 14 |
| Benazepril Hcl | Benazepril Hcl | 47 | 12 |
| Bumetanide | Bumetanide | 47 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 47 | 13 |
| Jardiance | Empagliflozin | 46 | suppressed |
| Ondansetron Odt | Ondansetron | 46 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 24 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 45 | suppressed |
| Prednisone | Prednisone | 45 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 43 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 35 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | suppressed |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Ezetimibe | Ezetimibe | 36 | 11 |
| Midodrine Hcl | Midodrine Hcl | 36 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 35 | suppressed |
| Gemtesa | Vibegron | 35 | suppressed |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Entresto | Sacubitril/Valsartan | 34 | 12 |
| Latanoprost | Latanoprost | 34 | 14 |
| Divalproex Sodium | Divalproex Sodium | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | 12 |
| Fluconazole | Fluconazole | 32 | 19 |
| Guanfacine Hcl | Guanfacine Hcl | 32 | 11 |
| Lidocaine | Lidocaine | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Mupirocin | Mupirocin | 30 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 17 |
| Estradiol | Estradiol | 24 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 22 | suppressed |
| Lacosamide | Lacosamide | 22 | suppressed |
| Phenobarbital | Phenobarbital | 22 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Ubrelvy | Ubrogepant | 21 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 20 | suppressed |
| Felodipine Er | Felodipine | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 19 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 19 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Scopolamine | Scopolamine | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 11 |
| Levofloxacin | Levofloxacin | 18 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 13 |
| Clonidine | Clonidine | 14 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Levemir | Insulin Detemir | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 12 | suppressed |
| Calcium Acetate | Calcium Acetate | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Meropenem | Meropenem | 11 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $445.77 · 25 records | GlaxoSmithKline, LLC. | BREZTRI, Cologuard Collection Kit, GEMTESA, MOUNJARO, RELISTOR, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Vafseo, XIFAXAN, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error